https://www.selleckchem.com/pr....oducts/anacardic-aci
In this mini review we focus on two potential niches for PLK1i that are supported by recent evidence triple negative breast cancers (TNBCs) and BRCA1-deficient cancers. On the one hand, we recollect several lines of strong evidence indicating that TNBCs are among the cancers with highest PLK1 expression and sensitivity to PLK1i. These findings are encouraging because of the limited therapeutics options available for TNBC patients, which rely mainly on classic chemotherapy. On the other hand, we discuss recent evidence that unveil
Gefällt mir
Kommentar
Teilen
